English
简体中文
Total: £ 56.28
Published Date: 2026-04-29 | Pages: 125 | Tables: 125 | Pharma & Healthcare
The global Drug-Induced Immune Hemolytic Anemia market was valued at US$ 4423 million in 2025 and is anticipated to reach US$ 6295 million by 2032, at a CAGR of 5.3% from 2026 to 2032.
Drug-Induced Immune Hemolytic Anemia (DIIHA) is an immune-mediated hematological disorder triggered by drugs, in which medications or their metabolites induce abnormal antibodies that mistakenly target and destroy red blood cells, leading to premature hemolysis and secondary anemia. It is commonly associated with antibiotics, anticancer agents, and immunomodulatory drugs, characterized by complex mechanisms, diagnostic challenges, and often under-recognized clinical manifestations. Symptoms include fatigue, jaundice, and laboratory signs of hemolysis, with severe cases potentially progressing to organ dysfunction. With the expansion of pharmacotherapy and widespread polypharmacy, DIIHA has become a critical focus in pharmacovigilance and hematologic disease management.The average gross profit margin of this product is 55%.
Against the backdrop of increasingly complex pharmacotherapy and evolving chronic disease management systems, the market related to drug-induced immune hemolytic anemia is showing growing potential. Industry analyses highlight that the rise in polypharmacy and the expansion of the aging population are increasing the number of high-risk patients, thereby driving demand for diagnostic testing and pharmacovigilance services. Meanwhile, regulatory emphasis on drug safety is encouraging healthcare systems to invest more in immune-related diagnostic capabilities. The development of biologics and targeted immunotherapies is also creating new intervention pathways for severe cases, accelerating the evolution of related diagnostic and therapeutic solutions.The primary challenges in this field lie in the rarity of the condition and the complexity of diagnosis. Due to variability in antibody types and inconsistent serological findings, DIIHA is often misdiagnosed or overlooked, as it can mimic autoimmune hemolytic anemia or transfusion reactions. Studies indicate that inconsistent laboratory findings significantly increase diagnostic difficulty and delay treatment. In addition, limited awareness among clinicians and the lack of standardized diagnostic protocols constrain market expansion. Increasing regulatory requirements for drug safety further raise compliance and validation costs for industry participants.From the demand perspective, the market is evolving from isolated clinical diagnosis toward an integrated system encompassing detection, monitoring, and risk management. Hospitals and reference laboratories are strengthening their capabilities in screening drug-related immune reactions, promoting the adoption of high-sensitivity antibody detection technologies. At the same time, the advancement of precision medicine is driving demand for individualized drug risk assessment. With the growing use of immunotherapies and novel pharmaceuticals, the need for adverse event management is expected to expand continuously, forming a stable long-term demand base.Upstream components in this field primarily include diagnostic reagents, antibody detection systems, blood sample processing materials, and biological reagents. High-quality antigens, antibodies, and standardized testing systems are critical for accurate diagnosis, directly affecting sensitivity and specificity. With advancements in in vitro diagnostic technologies, upstream supply is shifting toward higher purity, bioengineered solutions, and standardized production. Meanwhile, advanced diagnostic technologies still rely on sophisticated instruments and reagent systems, driving the industry toward greater technological intensity. Supply chain stability and quality control capabilities have become key competitive factors for manufacturers.
This report delivers a comprehensive overview of the global Drug-Induced Immune Hemolytic Anemia market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Drug-Induced Immune Hemolytic Anemia. The Drug-Induced Immune Hemolytic Anemia market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Drug-Induced Immune Hemolytic Anemia market comprehensively. Regional market sizes by Type, by Application, by Sales Channel, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Drug-Induced Immune Hemolytic Anemia manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bio-Rad Laboratories
Danaher Corporation
Ortho Clinical Diagnostics
Immucor
Grifols
Biomedomics
Roche
Novartis
Pfizer
Sanofi
Teva Pharmaceutical Industries
Viatris
Lupin
Incyte
Rigel Pharmaceuticals
Alpine Immune Sciences
Agios Pharmaceuticals
Segment by Type
Treatment
Diagnostics
Segment by Sales Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Patient Group
Elderly Patients
Chronic Patients
Oncology Patients
Segment by Application
Hospital Based Management
Outpatient Management
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Sales Channel, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Drug-Induced Immune Hemolytic Anemia companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Treatment
1.2.3 Diagnostics
1.3 Market by Sales Channel
1.3.1 Global Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Sales Channel: 2021 vs 2025 vs 2032
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Market by Patient Group
1.4.1 Global Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Patient Group: 2021 vs 2025 vs 2032
1.4.2 Elderly Patients
1.4.3 Chronic Patients
1.4.4 Oncology Patients
1.5 Market by Application
1.5.1 Global Drug-Induced Immune Hemolytic Anemia Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Hospital Based Management
1.5.3 Outpatient Management
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Drug-Induced Immune Hemolytic Anemia Market Perspective (2021–2032)
2.2 Global Drug-Induced Immune Hemolytic Anemia Growth Trends by Region
2.2.1 Global Drug-Induced Immune Hemolytic Anemia Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Drug-Induced Immune Hemolytic Anemia Historic Market Size by Region (2021–2026)
2.2.3 Drug-Induced Immune Hemolytic Anemia Forecasted Market Size by Region (2027–2032)
2.3 Drug-Induced Immune Hemolytic Anemia Market Dynamics
2.3.1 Drug-Induced Immune Hemolytic Anemia Industry Trends
2.3.2 Drug-Induced Immune Hemolytic Anemia Market Drivers
2.3.3 Drug-Induced Immune Hemolytic Anemia Market Challenges
2.3.4 Drug-Induced Immune Hemolytic Anemia Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug-Induced Immune Hemolytic Anemia Players by Revenue
3.1.1 Global Top Drug-Induced Immune Hemolytic Anemia Players by Revenue (2021–2026)
3.1.2 Global Drug-Induced Immune Hemolytic Anemia Revenue Market Share by Players (2021–2026)
3.2 Global Top Drug-Induced Immune Hemolytic Anemia Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Drug-Induced Immune Hemolytic Anemia Revenue
3.4 Global Drug-Induced Immune Hemolytic Anemia Market Concentration Ratio
3.4.1 Global Drug-Induced Immune Hemolytic Anemia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug-Induced Immune Hemolytic Anemia Revenue in 2025
3.5 Global Key Players of Drug-Induced Immune Hemolytic Anemia Head Offices and Areas Served
3.6 Global Key Players of Drug-Induced Immune Hemolytic Anemia, Products and Applications
3.7 Global Key Players of Drug-Induced Immune Hemolytic Anemia, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Drug-Induced Immune Hemolytic Anemia Breakdown Data by Type
4.1 Global Drug-Induced Immune Hemolytic Anemia Historic Market Size by Type (2021–2026)
4.2 Global Drug-Induced Immune Hemolytic Anemia Forecasted Market Size by Type (2027–2032)
5 Drug-Induced Immune Hemolytic Anemia Breakdown Data by Application
5.1 Global Drug-Induced Immune Hemolytic Anemia Historic Market Size by Application (2021–2026)
5.2 Global Drug-Induced Immune Hemolytic Anemia Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Drug-Induced Immune Hemolytic Anemia Market Size (2021–2032)
6.2 North America Drug-Induced Immune Hemolytic Anemia Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Drug-Induced Immune Hemolytic Anemia Market Size by Country (2021–2026)
6.4 North America Drug-Induced Immune Hemolytic Anemia Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug-Induced Immune Hemolytic Anemia Market Size (2021–2032)
7.2 Europe Drug-Induced Immune Hemolytic Anemia Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Drug-Induced Immune Hemolytic Anemia Market Size by Country (2021–2026)
7.4 Europe Drug-Induced Immune Hemolytic Anemia Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size (2021–2032)
8.2 Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size by Region (2021–2026)
8.4 Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Drug-Induced Immune Hemolytic Anemia Market Size (2021–2032)
9.2 Latin America Drug-Induced Immune Hemolytic Anemia Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Drug-Induced Immune Hemolytic Anemia Market Size by Country (2021–2026)
9.4 Latin America Drug-Induced Immune Hemolytic Anemia Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size (2021–2032)
10.2 Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size by Country (2021–2026)
10.4 Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bio-Rad Laboratories
11.1.1 Bio-Rad Laboratories Company Details
11.1.2 Bio-Rad Laboratories Business Overview
11.1.3 Bio-Rad Laboratories Drug-Induced Immune Hemolytic Anemia Introduction
11.1.4 Bio-Rad Laboratories Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.1.5 Bio-Rad Laboratories Recent Development
11.2 Danaher Corporation
11.2.1 Danaher Corporation Company Details
11.2.2 Danaher Corporation Business Overview
11.2.3 Danaher Corporation Drug-Induced Immune Hemolytic Anemia Introduction
11.2.4 Danaher Corporation Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.2.5 Danaher Corporation Recent Development
11.3 Ortho Clinical Diagnostics
11.3.1 Ortho Clinical Diagnostics Company Details
11.3.2 Ortho Clinical Diagnostics Business Overview
11.3.3 Ortho Clinical Diagnostics Drug-Induced Immune Hemolytic Anemia Introduction
11.3.4 Ortho Clinical Diagnostics Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.3.5 Ortho Clinical Diagnostics Recent Development
11.4 Immucor
11.4.1 Immucor Company Details
11.4.2 Immucor Business Overview
11.4.3 Immucor Drug-Induced Immune Hemolytic Anemia Introduction
11.4.4 Immucor Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.4.5 Immucor Recent Development
11.5 Grifols
11.5.1 Grifols Company Details
11.5.2 Grifols Business Overview
11.5.3 Grifols Drug-Induced Immune Hemolytic Anemia Introduction
11.5.4 Grifols Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.5.5 Grifols Recent Development
11.6 Biomedomics
11.6.1 Biomedomics Company Details
11.6.2 Biomedomics Business Overview
11.6.3 Biomedomics Drug-Induced Immune Hemolytic Anemia Introduction
11.6.4 Biomedomics Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.6.5 Biomedomics Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Drug-Induced Immune Hemolytic Anemia Introduction
11.7.4 Roche Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.7.5 Roche Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Drug-Induced Immune Hemolytic Anemia Introduction
11.8.4 Novartis Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.8.5 Novartis Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Drug-Induced Immune Hemolytic Anemia Introduction
11.9.4 Pfizer Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.9.5 Pfizer Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Drug-Induced Immune Hemolytic Anemia Introduction
11.10.4 Sanofi Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.10.5 Sanofi Recent Development
11.11 Teva Pharmaceutical Industries
11.11.1 Teva Pharmaceutical Industries Company Details
11.11.2 Teva Pharmaceutical Industries Business Overview
11.11.3 Teva Pharmaceutical Industries Drug-Induced Immune Hemolytic Anemia Introduction
11.11.4 Teva Pharmaceutical Industries Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.11.5 Teva Pharmaceutical Industries Recent Development
11.12 Viatris
11.12.1 Viatris Company Details
11.12.2 Viatris Business Overview
11.12.3 Viatris Drug-Induced Immune Hemolytic Anemia Introduction
11.12.4 Viatris Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.12.5 Viatris Recent Development
11.13 Lupin
11.13.1 Lupin Company Details
11.13.2 Lupin Business Overview
11.13.3 Lupin Drug-Induced Immune Hemolytic Anemia Introduction
11.13.4 Lupin Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.13.5 Lupin Recent Development
11.14 Incyte
11.14.1 Incyte Company Details
11.14.2 Incyte Business Overview
11.14.3 Incyte Drug-Induced Immune Hemolytic Anemia Introduction
11.14.4 Incyte Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.14.5 Incyte Recent Development
11.15 Rigel Pharmaceuticals
11.15.1 Rigel Pharmaceuticals Company Details
11.15.2 Rigel Pharmaceuticals Business Overview
11.15.3 Rigel Pharmaceuticals Drug-Induced Immune Hemolytic Anemia Introduction
11.15.4 Rigel Pharmaceuticals Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.15.5 Rigel Pharmaceuticals Recent Development
11.16 Alpine Immune Sciences
11.16.1 Alpine Immune Sciences Company Details
11.16.2 Alpine Immune Sciences Business Overview
11.16.3 Alpine Immune Sciences Drug-Induced Immune Hemolytic Anemia Introduction
11.16.4 Alpine Immune Sciences Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.16.5 Alpine Immune Sciences Recent Development
11.17 Agios Pharmaceuticals
11.17.1 Agios Pharmaceuticals Company Details
11.17.2 Agios Pharmaceuticals Business Overview
11.17.3 Agios Pharmaceuticals Drug-Induced Immune Hemolytic Anemia Introduction
11.17.4 Agios Pharmaceuticals Revenue in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
11.17.5 Agios Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Treatment
Table 3. Key Players of Diagnostics
Table 4. Global Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Sales Channel (US$ Million): 2021 vs 2025 vs 2032
Table 5. Key Players of Hospital Pharmacies
Table 6. Key Players of Retail Pharmacies
Table 7. Key Players of Online Pharmacies
Table 8. Global Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Patient Group (US$ Million): 2021 vs 2025 vs 2032
Table 9. Key Players of Elderly Patients
Table 10. Key Players of Chronic Patients
Table 11. Key Players of Oncology Patients
Table 12. Global Drug-Induced Immune Hemolytic Anemia Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 13. Global Drug-Induced Immune Hemolytic Anemia Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 14. Global Drug-Induced Immune Hemolytic Anemia Market Size by Region (US$ Million), 2021–2026
Table 15. Global Drug-Induced Immune Hemolytic Anemia Market Share by Region (2021–2026)
Table 16. Global Drug-Induced Immune Hemolytic Anemia Forecasted Market Size by Region (US$ Million), 2027–2032
Table 17. Global Drug-Induced Immune Hemolytic Anemia Market Share by Region (2027–2032)
Table 18. Drug-Induced Immune Hemolytic Anemia Market Trends
Table 19. Drug-Induced Immune Hemolytic Anemia Market Drivers
Table 20. Drug-Induced Immune Hemolytic Anemia Market Challenges
Table 21. Drug-Induced Immune Hemolytic Anemia Market Restraints
Table 22. Global Drug-Induced Immune Hemolytic Anemia Revenue by Players (US$ Million), 2021–2026
Table 23. Global Drug-Induced Immune Hemolytic Anemia Market Share by Players (2021–2026)
Table 24. Global Top Drug-Induced Immune Hemolytic Anemia Players by Tier (Tier 1, Tier 2, and Tier 3), based on Drug-Induced Immune Hemolytic Anemia Revenue, 2025
Table 25. Ranking of Global Top Drug-Induced Immune Hemolytic Anemia Companies by Revenue (US$ Million) in 2025
Table 26. Global 5 Largest Players Market Share by Drug-Induced Immune Hemolytic Anemia Revenue (CR5 and HHI), 2021–2026
Table 27. Global Key Players of Drug-Induced Immune Hemolytic Anemia, Headquarters and Area Served
Table 28. Global Key Players of Drug-Induced Immune Hemolytic Anemia, Products and Applications
Table 29. Global Key Players of Drug-Induced Immune Hemolytic Anemia, Date of General Availability (GA)
Table 30. Mergers and Acquisitions, Expansion Plans
Table 31. Global Drug-Induced Immune Hemolytic Anemia Market Size by Type (US$ Million), 2021–2026
Table 32. Global Drug-Induced Immune Hemolytic Anemia Revenue Market Share by Type (2021–2026)
Table 33. Global Drug-Induced Immune Hemolytic Anemia Forecasted Market Size by Type (US$ Million), 2027–2032
Table 34. Global Drug-Induced Immune Hemolytic Anemia Revenue Market Share by Type (2027–2032)
Table 35. Global Drug-Induced Immune Hemolytic Anemia Market Size by Application (US$ Million), 2021–2026
Table 36. Global Drug-Induced Immune Hemolytic Anemia Revenue Market Share by Application (2021–2026)
Table 37. Global Drug-Induced Immune Hemolytic Anemia Forecasted Market Size by Application (US$ Million), 2027–2032
Table 38. Global Drug-Induced Immune Hemolytic Anemia Revenue Market Share by Application (2027–2032)
Table 39. North America Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 40. North America Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2021–2026
Table 41. North America Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2027–2032
Table 42. Europe Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Europe Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2021–2026
Table 44. Europe Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2027–2032
Table 45. Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 46. Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size by Region (US$ Million), 2021–2026
Table 47. Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size by Region (US$ Million), 2027–2032
Table 48. Latin America Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 49. Latin America Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2021–2026
Table 50. Latin America Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2027–2032
Table 51. Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 52. Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2021–2026
Table 53. Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size by Country (US$ Million), 2027–2032
Table 54. Bio-Rad Laboratories Company Details
Table 55. Bio-Rad Laboratories Business Overview
Table 56. Bio-Rad Laboratories Drug-Induced Immune Hemolytic Anemia Product
Table 57. Bio-Rad Laboratories Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 58. Bio-Rad Laboratories Recent Development
Table 59. Danaher Corporation Company Details
Table 60. Danaher Corporation Business Overview
Table 61. Danaher Corporation Drug-Induced Immune Hemolytic Anemia Product
Table 62. Danaher Corporation Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 63. Danaher Corporation Recent Development
Table 64. Ortho Clinical Diagnostics Company Details
Table 65. Ortho Clinical Diagnostics Business Overview
Table 66. Ortho Clinical Diagnostics Drug-Induced Immune Hemolytic Anemia Product
Table 67. Ortho Clinical Diagnostics Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 68. Ortho Clinical Diagnostics Recent Development
Table 69. Immucor Company Details
Table 70. Immucor Business Overview
Table 71. Immucor Drug-Induced Immune Hemolytic Anemia Product
Table 72. Immucor Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 73. Immucor Recent Development
Table 74. Grifols Company Details
Table 75. Grifols Business Overview
Table 76. Grifols Drug-Induced Immune Hemolytic Anemia Product
Table 77. Grifols Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 78. Grifols Recent Development
Table 79. Biomedomics Company Details
Table 80. Biomedomics Business Overview
Table 81. Biomedomics Drug-Induced Immune Hemolytic Anemia Product
Table 82. Biomedomics Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 83. Biomedomics Recent Development
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Drug-Induced Immune Hemolytic Anemia Product
Table 87. Roche Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 88. Roche Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Drug-Induced Immune Hemolytic Anemia Product
Table 92. Novartis Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 93. Novartis Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Drug-Induced Immune Hemolytic Anemia Product
Table 97. Pfizer Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 98. Pfizer Recent Development
Table 99. Sanofi Company Details
Table 100. Sanofi Business Overview
Table 101. Sanofi Drug-Induced Immune Hemolytic Anemia Product
Table 102. Sanofi Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 103. Sanofi Recent Development
Table 104. Teva Pharmaceutical Industries Company Details
Table 105. Teva Pharmaceutical Industries Business Overview
Table 106. Teva Pharmaceutical Industries Drug-Induced Immune Hemolytic Anemia Product
Table 107. Teva Pharmaceutical Industries Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 108. Teva Pharmaceutical Industries Recent Development
Table 109. Viatris Company Details
Table 110. Viatris Business Overview
Table 111. Viatris Drug-Induced Immune Hemolytic Anemia Product
Table 112. Viatris Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 113. Viatris Recent Development
Table 114. Lupin Company Details
Table 115. Lupin Business Overview
Table 116. Lupin Drug-Induced Immune Hemolytic Anemia Product
Table 117. Lupin Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 118. Lupin Recent Development
Table 119. Incyte Company Details
Table 120. Incyte Business Overview
Table 121. Incyte Drug-Induced Immune Hemolytic Anemia Product
Table 122. Incyte Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 123. Incyte Recent Development
Table 124. Rigel Pharmaceuticals Company Details
Table 125. Rigel Pharmaceuticals Business Overview
Table 126. Rigel Pharmaceuticals Drug-Induced Immune Hemolytic Anemia Product
Table 127. Rigel Pharmaceuticals Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 128. Rigel Pharmaceuticals Recent Development
Table 129. Alpine Immune Sciences Company Details
Table 130. Alpine Immune Sciences Business Overview
Table 131. Alpine Immune Sciences Drug-Induced Immune Hemolytic Anemia Product
Table 132. Alpine Immune Sciences Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 133. Alpine Immune Sciences Recent Development
Table 134. Agios Pharmaceuticals Company Details
Table 135. Agios Pharmaceuticals Business Overview
Table 136. Agios Pharmaceuticals Drug-Induced Immune Hemolytic Anemia Product
Table 137. Agios Pharmaceuticals Revenue in Drug-Induced Immune Hemolytic Anemia Business (US$ Million), 2021–2026
Table 138. Agios Pharmaceuticals Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
Table 142. Authors List of This Report
List of Figures
Figure 1. Drug-Induced Immune Hemolytic Anemia Picture
Figure 2. Global Drug-Induced Immune Hemolytic Anemia Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Drug-Induced Immune Hemolytic Anemia Market Share by Type: 2025 vs 2032
Figure 4. Treatment Features
Figure 5. Diagnostics Features
Figure 6. Global Drug-Induced Immune Hemolytic Anemia Market Size Comparison by Sales Channel (US$ Million), 2021–2032
Figure 7. Hospital Pharmacies Features
Figure 8. Retail Pharmacies Features
Figure 9. Online Pharmacies Features
Figure 10. Global Drug-Induced Immune Hemolytic Anemia Market Size Comparison by Patient Group (US$ Million), 2021–2032
Figure 11. Elderly Patients Features
Figure 12. Chronic Patients Features
Figure 13. Oncology Patients Features
Figure 14. Global Drug-Induced Immune Hemolytic Anemia Market Size by Application (US$ Million), 2021–2032
Figure 15. Global Drug-Induced Immune Hemolytic Anemia Market Share by Application: 2025 vs 2032
Figure 16. Hospital Based Management Case Studies
Figure 17. Outpatient Management Case Studies
Figure 18. Drug-Induced Immune Hemolytic Anemia Report Years Considered
Figure 19. Global Drug-Induced Immune Hemolytic Anemia Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 20. Global Drug-Induced Immune Hemolytic Anemia Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Drug-Induced Immune Hemolytic Anemia Market Share by Region: 2025 vs 2032
Figure 22. Global Drug-Induced Immune Hemolytic Anemia Market Share by Players in 2025
Figure 23. Global Drug-Induced Immune Hemolytic Anemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. The Top 10 and 5 Players Market Share by Drug-Induced Immune Hemolytic Anemia Revenue in 2025
Figure 25. North America Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. North America Drug-Induced Immune Hemolytic Anemia Market Share by Country (2021–2032)
Figure 27. United States Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Canada Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Europe Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Europe Drug-Induced Immune Hemolytic Anemia Market Share by Country (2021–2032)
Figure 31. Germany Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. France Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. U.K. Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Italy Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Russia Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Ireland Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Asia-Pacific Drug-Induced Immune Hemolytic Anemia Market Share by Region (2021–2032)
Figure 39. China Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Japan Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. South Korea Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Southeast Asia Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. India Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Australia & New Zealand Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Latin America Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Latin America Drug-Induced Immune Hemolytic Anemia Market Share by Country (2021–2032)
Figure 47. Mexico Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Brazil Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Middle East & Africa Drug-Induced Immune Hemolytic Anemia Market Share by Country (2021–2032)
Figure 51. Israel Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Saudi Arabia Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. UAE Drug-Induced Immune Hemolytic Anemia Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Bio-Rad Laboratories Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 55. Danaher Corporation Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 56. Ortho Clinical Diagnostics Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 57. Immucor Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 58. Grifols Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 59. Biomedomics Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 60. Roche Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 61. Novartis Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 62. Pfizer Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 63. Sanofi Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 64. Teva Pharmaceutical Industries Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 65. Viatris Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 66. Lupin Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 67. Incyte Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 68. Rigel Pharmaceuticals Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 69. Alpine Immune Sciences Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 70. Agios Pharmaceuticals Revenue Growth Rate in Drug-Induced Immune Hemolytic Anemia Business (2021–2026)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
